The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial
Abstract
OBJECTIVE: Painful diabetic peripheral neuropathy (DPN) may not be adequately managed with available therapeutic options. This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN. RESEARCH DESIGN AND METHODS: Patients (n = 588) with at least a 3-month history of opioid and/or non-opioid analgesic use for DPN, dissatisfaction with current treatment, and an average pain intensity score of at least 5 on an 11-point numerical rating scale (NRS; 0 = 'no pain,' 10 = 'pain as bad as you can imagine') were titrated to an optimal dose of tapentadol ER (100-250 mg bid) during a 3-week open-label phase. Subsequently, patients (n = 395) with at least a 1-point reduction in pain intensity were randomized 1:1 to receive placebo or the optimal fixed dose of tapentadol ER determined during the open-label phase for a 12-week double-blind phase. CLINICAL TRIAL REGISTRATION: NCT00455520. MAIN OUTCOME MEASURES: The primary efficacy outcome was the change in average pain intensity from randomization, determined by twice-daily NRS measurements. Safety was assessed throughout the study. RESULTS: The least-squares mean difference between groups in the change in average pain intensity from the start of double-blind treatment to week 12 was -1.3 (95% confidence interval, -1.70 to -0.92; p < 0.001, tapentadol ER vs. placebo). A total of 60.5% (356/588) of patients reported at least a 30% improvement in pain intensity from the start to the end of the open-label titration phase; of the patients who were randomized to tapentadol ER, 53.6% (105/196) reported at least a 30% improvement from pre-titration to week 12 of the double-blind phase. The most common treatment-emergent adverse events that occurred during double-blind treatment with tapentadol ER included nausea, anxiety, diarrhea, and dizziness. Potential limitations of this study are related to the enriched enrollment randomized-withdrawal trial design, which may result in a more homogeneous patient population during double-blind treatment and may present a risk of unblinding because of changes in side effects from the open-label to the double-blind phase. CONCLUSIONS: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., Kerns, R. D., Stucki, G., Allen, R. R., Bellamy, N., et al. (2005) · Pain · doi:10.1016/j.pain.2004.09.012 · Cited by 3,732
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, J. T., Galer, B. S., et al. (2003) · Pain · doi:10.1016/j.pain.2003.08.001 · Cited by 3,510
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Self-citationPharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M., Hansson, P., Jensen, T. S., Nurmikko, T., Sampaio, C., Sindrup, S., & Wiffen, P. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 880
Duloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858
Rosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725
Efficacy of oxycodone in neuronathic pain: A randomized trial in postherpetic neuralgia
N. Watson, C. P., & Babul, N. (1998) · Neurology · doi:10.1212/wnl.50.6.1837 · Cited by 646
Two New Rating Scales for Opiate Withdrawal
Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998709001515 · Cited by 599
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy
Harati, Y., Gooch, C., Swenson, M., Edelman, S., Greene, D., Raskin, P., Donofrio, P., Cornblath, D., Sachdeo, R., Siu, C. O., et al. (1998) · Neurology · doi:10.1212/wnl.50.6.1842 · Cited by 546
Raskin, J., Pritchett, Y. L., Wang, F., D'Souza, D. N., Waninger, A. L., Iyengar, S., & Wernicke, J. F. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 532
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Watson, P. C. N., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00160-x · Cited by 510
Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003) · Neurology · doi:10.1212/01.wnl.0000057720.36503.2c · Cited by 469
Eisenberg, E., McNicol, E. D., & Carr, D. B. (2005) · JAMA · doi:10.1001/jama.293.24.3043 · Cited by 407
Tzschentke, T. M., Christoph, T., Kögel, B., Schiene, K., Hennies, H.-H., Englberger, W., Haurand, M., Jahnel, U., Cremers, T. I. F. H., Friderichs, E., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.126052 · Cited by 395
Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options
Veves, A., Backonja, M., & Malik, R. A. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00347.x · Cited by 375
Freeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322
Roth, S. H., Fleischmann, R. M., Burch, F. X., Dietz, F., Bockow, B., Rapoport, R. J., Rutstein, J., & Lacouture, P. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.853 · Cited by 306
Buynak, R., Shapiro, D. Y., Okamoto, A., Hove, I. V., Rauschkolb, C., Steup, A., Lange, B., Lange, C., & Etropolski, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.497720 · Cited by 252
Self-citationCrofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236
Afilalo, M., Etropolski, M. S., Kuperwasser, B., Kelly, K., Okamoto, A., Van Hove, I., Steup, A., Lange, B., Rauschkolb, C., & Haeussler, J. (2010) · Clinical Drug Investigation · doi:10.2165/11533440-000000000-00000 · Cited by 228
Self-citationQuilici, S., Chancellor, J., Löthgren, M., Simon, D., Said, G., Le, T. K., Garcia-Cebrian, A., & Monz, B. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-6 · Cited by 223
Caldwell, J. R., Rapoport, R. J., Davis, J. C., Offenberg, H. L., Marker, H. W., Roth, S. H., Yuan, W., Eliot, L., Babul, N., & Lynch, P. M. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00383-4 · Cited by 219
Arezzo, J. C., Rosenstock, J., LaMoreaux, L., & Pauer, L. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-33 · Cited by 190
Wild, J. E., Grond, S., Kuperwasser, B., Gilbert, J., McCann, B., Lange, B., Steup, A., Häufel, T., Etropolski, M. S., Rauschkolb, C., et al. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00397.x · Cited by 179
Self-citationByas-Smith, M. G., Max, M. B., Muir, J., & Kingman, A. (1995) · Pain · doi:10.1016/0304-3959(94)00121-t · Cited by 177
Lange, B., Kuperwasser, B., Okamoto, A., Steup, A., Häufel, T., Ashworth, J., & Etropolski, M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0036-3 · Cited by 172
Self-citationHale, M. E., Ahdieh, H., Ma, T., & Rauck, R. (2007) · The Journal of Pain · doi:10.1016/j.jpain.2006.09.011 · Cited by 169
Hale, M. E., Dvergsten, C., & Gimbel, J. S. (2004) · Journal of Pain · doi:10.1016/j.jpain.2004.09.005 · Cited by 162
Consensus Guidelines: Treatment Planning and Options
Argoff, C. E., Backonja, M.-M., Belgrade, M. J., Bennett, G. J., Clark, M. R., Cole, B. E., Fishbain, D. A., Irving, G. A., McCarberg, B. H., & McLean, M. J. (2006) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61475-4 · Cited by 158
Katz, N., Rauck, R., Ahdieh, H., Ma, T., van der Hoop, R. G., Kerwin, R., & Podolsky, G. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162692 · Cited by 139
Tschentke, T. M., Vry, J. D., Terlinden, R., et al. (2006) · Drugs of the Future · doi:10.1358/dof.2006.031.12.1047744 · Cited by 123
Matsumoto, A. K., Babul, N., & Ahdieh, H. B. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00057.x · Cited by 118
McQuay, H. J., Derry, S., Moore, A. R., Poulain, P., & Legout, V. (2008) · Pain · doi:10.1016/j.pain.2008.01.014 · Cited by 106
Kivitz, A., Ma, C., Ahdieh, H. B., & Galer, B. S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.008 · Cited by 81
Lynch, M. E., Clark, A. J., & Sawynok, J. (2003) · Pain · doi:10.1016/s0304-3959(02)00419-0 · Cited by 81
What is new in neuropathic pain?
Davis, M. P. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0156-0 · Cited by 77
Enriched Enrollment Randomized Withdrawal Trial Designs of Analgesics
Katz, N. P. (2009) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181b12dec · Cited by 76
A Cluster Study of Predictors of Severe West Nile Virus Infection
Abroug, F., Ouanes-Besbes, L., Letaief, M., Romdhane, F. B., Khairallah, M., Triki, H., & Bouzouiaia, N. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.1.12 · Cited by 63
Chronic low back pain analgesic studies – A methodological minefield
Moore, A. R., Straube, S., Derry, S., & McQuay, H. J. (2010) · Pain · doi:10.1016/j.pain.2010.02.032 · Cited by 46
Staud, R., & Price, D. D. (2008) · Pain · doi:10.1016/j.pain.2008.03.005 · Cited by 39
Peniston, J. H., & Gould, E. M. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.019 · Cited by 26
Quessy, S. N. (2009) · Pain · doi:10.1016/j.pain.2009.10.029 · Cited by 21
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.18472 · Cited by 716
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Metadata
- Authors
- Schwartz, S., Etropolski, M., Shapiro, D. Y., Okamoto, A., Lange, R., Haeussler, J., & Rauschkolb, C.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2010-12-17
- Volume
- 27
- Issue
- 1
- Pages
- 151-162
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2028140282
- Cited by
- 262
- References
- 48
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.